96 related articles for article (PubMed ID: 26902334)
41. [Current status of castration resistant prostate cancer basic research].
Sakamoto S; Ichikawa T
Nihon Rinsho; 2014 Dec; 72(12):2097-102. PubMed ID: 25518340
[TBL] [Abstract][Full Text] [Related]
42. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
43. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
[TBL] [Abstract][Full Text] [Related]
44. PADI2-Mediated Citrullination Promotes Prostate Cancer Progression.
Wang L; Song G; Zhang X; Feng T; Pan J; Chen W; Yang M; Bai X; Pang Y; Yu J; Han J; Han B
Cancer Res; 2017 Nov; 77(21):5755-5768. PubMed ID: 28819028
[TBL] [Abstract][Full Text] [Related]
45. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
[TBL] [Abstract][Full Text] [Related]
46. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
Ponnusamy S; Coss CC; Thiyagarajan T; Watts K; Hwang DJ; He Y; Selth LA; McEwan IJ; Duke CB; Pagadala J; Singh G; Wake RW; Ledbetter C; Tilley WD; Moldoveanu T; Dalton JT; Miller DD; Narayanan R
Cancer Res; 2017 Nov; 77(22):6282-6298. PubMed ID: 28978635
[TBL] [Abstract][Full Text] [Related]
47. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
48. Punctuated evolution of prostate cancer genomes.
Baca SC; Prandi D; Lawrence MS; Mosquera JM; Romanel A; Drier Y; Park K; Kitabayashi N; MacDonald TY; Ghandi M; Van Allen E; Kryukov GV; Sboner A; Theurillat JP; Soong TD; Nickerson E; Auclair D; Tewari A; Beltran H; Onofrio RC; Boysen G; Guiducci C; Barbieri CE; Cibulskis K; Sivachenko A; Carter SL; Saksena G; Voet D; Ramos AH; Winckler W; Cipicchio M; Ardlie K; Kantoff PW; Berger MF; Gabriel SB; Golub TR; Meyerson M; Lander ES; Elemento O; Getz G; Demichelis F; Rubin MA; Garraway LA
Cell; 2013 Apr; 153(3):666-77. PubMed ID: 23622249
[TBL] [Abstract][Full Text] [Related]
49. Typing tumors using pathways selected by somatic evolution.
Wang S; Ma J; Zhang W; Shen JP; Huang J; Peng J; Ideker T
Nat Commun; 2018 Oct; 9(1):4159. PubMed ID: 30297789
[TBL] [Abstract][Full Text] [Related]
50. Prostate cancer: Multifocal disease--independent clonal lineages in malignant nodules and even in normal tissue.
Thoma C
Nat Rev Urol; 2015 Apr; 12(4):177. PubMed ID: 25782174
[No Abstract] [Full Text] [Related]
51. Clinical and genomic features of a subtype of prostate cancer.
Venkatesan P
Lancet Oncol; 2018 Aug; 19(8):e394. PubMed ID: 30033225
[No Abstract] [Full Text] [Related]
52. Mel Greaves: Cancer through the Lens of Evolution.
Trends Cancer; 2016 Oct; 2(10):539-541. PubMed ID: 27904886
[No Abstract] [Full Text] [Related]
53. Mutation signatures reveal clonal evolution.
Lee YS; van Galen P
Blood; 2023 May; 141(19):2292-2293. PubMed ID: 37166926
[No Abstract] [Full Text] [Related]
54. Positive selection as the unifying force for clonal evolution in multiple myeloma.
Diamond B; Yellapantula V; Rustad EH; Maclachlan KH; Mayerhoefer M; Kaiser M; Morgan G; Landgren O; Maura F
Leukemia; 2021 May; 35(5):1511-1515. PubMed ID: 33483619
[No Abstract] [Full Text] [Related]
55. Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma.
Tabanelli V; Melle F; Motta G; Mazzara S; Fabbri M; Corsini C; Gerbino E; Calleri A; Sapienza MR; Abbene I; Stufano V; Barberis M; Pileri SA
Haematologica; 2020 Aug; 105(8):e432-e436. PubMed ID: 32467139
[No Abstract] [Full Text] [Related]
56. Autosomal Clonal Monoallelic Expression: Natural or Artifactual?
Rv P; Sundaresh A; Karunyaa M; Arun A; Gayen S
Trends Genet; 2021 Mar; 37(3):206-211. PubMed ID: 33234351
[TBL] [Abstract][Full Text] [Related]
57. Efficient Algorithms Unlock Understanding of Clonal Evolution in Cancer.
Miller CA
Blood Cancer Discov; 2022 May; 3(3):176-177. PubMed ID: 35510362
[TBL] [Abstract][Full Text] [Related]
58. Genomic clonal evolution correlated with phenotype and prognosis in gastric cancer.
Ge J; Li X; Deng Z; Gao X; Liu Y; Xiong X; Zhao X; Peng H; Yi X; Xia X; Chen Z; Li L; Zhou H; Liu H
Clin Transl Med; 2022 Apr; 12(4):e799. PubMed ID: 35384329
[No Abstract] [Full Text] [Related]
59. Prostate-specific Membrane Antigen-targeted Isotope Therapy: Inherent Challenges Owing to Heterogeneity and Clonal Evolution.
Sartor O
Eur Urol; 2024 Mar; 85(3):205-206. PubMed ID: 38176993
[No Abstract] [Full Text] [Related]
60. Androgen receptor, neovascularization and liver cancer metastasis.
Feng MW; Hanley KL; Feng GS
J Hepatol; 2021 Oct; 75(4):768-769. PubMed ID: 34233845
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
